Novel Dual-Target Kinase Inhibitors of EGFR and ALK Were Designed, Synthesized, and Induced Cell Apoptosis in Non-Small Cell Lung Cancer

ALK-positive NSCLC coexisting with EGFR mutations is a frequently occurring clinical phenomenon. Targeting ALK and EGFR simultaneously may be an effective way to treat these cancer patients. In this study, we designed and synthesized ten new dual-target EGFR/ALK inhibitors. Among them, the optimal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yangyang, Li, Wei, Nie, Wenyan, Yao, Han, Ren, Yuanyuan, Wang, Mengxuan, Nie, Haoran, Gu, Chenxi, Liu, Jiadai, An, Baijiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004195/
https://www.ncbi.nlm.nih.gov/pubmed/36903251
http://dx.doi.org/10.3390/molecules28052006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004195/
https://www.ncbi.nlm.nih.gov/pubmed/36903251
http://dx.doi.org/10.3390/molecules28052006

Ejemplares similares